MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis

Gynecologic Oncology

Volumn 110, Issue 2, 2008, Pages 206-215

  Boren, Todd ^a,b   Xiong, Yin ^a,b   Hakam, Ardeshir ^d   Wenham, Robert ^a   Apte, Sachin ^a   Wei, ZhengZheng ^e   Kamath, Siddharth ^a,b   Chen, Dung Tsa ^c   Dressman, Holly ^e   Lancaster, Johnathan M ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b Cancer Prevention and Control   (United States)

^c Biostatistics Core   (United States)

^d Division of Anatomic Pathology   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Endometrial cancer; MessengerRNA; MicroRNA; Pathway analysis

Indexed keywords

MESSENGER RNA; MICRORNA;

ARTICLE; CANCER GENETICS; CARCINOGENESIS; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; RNA ANALYSIS; UNINDEXED SEQUENCE;

CELL TRANSFORMATION, NEOPLASTIC; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; MICRORNAS; NEOPLASM STAGING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 47249166414     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.03.023     Document Type: Article

References (40)

1. Ries L.A.G., Melbert D., Krapcho M., Mariotto A., Miller B.A., Feuer E.J., et al. SEER cancer statistics review (2007). http://seer.cancer.gov/csr/1975_2004/ [Internet Website] [cited 2007] Available from: http://seer.cancer.gov/csr/1975_2004/
2. Bidus M.A., Risinger J.I., Gadisetti V.R., Chandremouli G.V.R., Dainty L.A., Litzi T.J., et al. Prediction of lymph node metastasis in patients with endometrioid endometrial cancer using expression microarray. Clinical Cancer Res. 12 1 (2006) 83-88
3. Ferguson S.E., Olshen A.B., Viale A., Barakat R.R., and Boyd J. Stratification of intermediate-risk endometrial cancer patients into groups at high risk or low risk for recurrence based on tumor gene expression profiles. Clinical Cancer Res. 11 (2005) 2252-2257
4. Risinger J.I., Maxwell G.L., Chandremouli G.V.R., Jazaeri A., Aprelikova O., Patterson T., et al. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res 63 (2003) 6-11
5. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 (2004) 281-297
6. Filipowicz W., Jaskiewicz L., Kolb F.A., and Pillai R.S. Post-transcriptional gene silencing by siRNA and miRNAs. Curr Opin Struck Biol 15 (2005) 331-341
7. Sontheimer E.J., and Carthew R. Silence from within: endogenous siRNAs and miRNAs. Cell 122 (2005) 9-12
8. He L., Thompson J.M., Hermann M.T., Hernando-Monge E., Mu D., Goodson S., et al. A microRNA polycistron as a potential human oncogene. Nature 435 (2005) 828-833
9. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., et al. MicroRNA expression profiles that classify human cancers. Nature 435 (2005) 834-838
10. O'Donnell K.A., Wentzel E.A., Zeller K.I., Dang C.V., and Mendell J.T. c-myc-regulated microRNAs modulate E2F1 expression. Nature 435 (2005) 839-843
11. Iorio M., Ferracin M., Liu C.G., Veronese A., Spizzo R., Sabbioni S., et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65 16 (2005) 7065-7070
12. Michael M.Z., O'Connor S.M., van Holst Pellekaan N.G., Young G.P., and James R.J. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 1 12 (2003) 882-891
13. Murakami Y., Yasuda T., Saigo K., Urashima T., Toyoda H., Okanoue T., et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma. Oncogene 25 (2006) 2537-2545
14. Volinia S., Calin G.A., Liu C.G., Ambs S., Cimmino A., Petrocca F., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103 3 (2006) 2257-2261
15. Yanaihara N., Caplen N., Bowman E., Seike M., Kumanmoto K., Yi M., et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9 3 (2006) 189-198
16. Griffiths-Jones S, Grocock RJ, Dongen Sv, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. In; 2006.
17. Hecht J.L., and Mutter G.L. Molecular and pathologc aspects of endometrial carcinogenesis. J Clin Oncol 24 29 (2006) 4783-4791
18. Matias-Guiu X., Catasus L., Bussaglia E., et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 32 (2001) 569-577
19. Mirabelli-Primdahl L., Gryfe R., Kim H., et al. Beta-Catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res 59 (1999) 3346-3351
20. Saegusa M., Hashimura M., Yoshida T., et al. Beta-Catenin mutations and abberant nuclear expression during endometrial tumorigenesis. Br J Cancer 84 (2001) 209-217
21. Koul A., Borg A., Pejovic T., et al. Identification of TP53 gene mutations in uterine corpus cancer with short follow-up. Gynecol Oncol 67 (1997) 295-302
22. Orbo A., Nilsen M., Arnes M., Petterson I., and Larsen K. Loss of expression of MLH1, MLH2, MSH6, and PTEN related to endometrial cancer in 68 patients with endometrial hyperplasia. Int J Gynecol Pathol 22 2 (2003) 141-148
23. Sugiyama Y., Shingo D., Yoshida Y., Akiyama F., Sugiyama K., Hirai Y., et al. A large scale gene expression comparison of microdissected, small sized endometrial cancers with or without hyperplasia matched to same-patient normal tissue. Clin Cancer Res 9 (2003) 5589-5600
24. Kugler A. Matrix metalloproteinases and their inhibitors. Anticancer Res 19 (1999) 1589-1592
25. Stetler-Stevenson W.G. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 103 (1999) 1237-1241
26. Maatta M., Soini Y., Liakka A., and Autio-Harmainen H. Localization of MT1-MMP, TIMP-1, TIMP-2, and TIMP-3 messenger RNA in normal, hyperplastic, and neoplastic endometrium. Enhanced expression by endometrial adenocarcinoma is associated with low differentiation. Am J Clin Pathol 114 3 (2000) 402-411
27. Smid-Koopman E., Blok L.J., Chadha-Ajwani S., Helmerhorst T.J., Brinkmann A.O., and Huikeshoven F.J. Gene expression profiles of human endometrial cancer samples using a cDNA-expression array technique: assessment of an analysis method. Br J Cancer 83 2 (2000) 246-251
28. Tunuguntla R., Ripley D., Sang Q.X., and Chegini N. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinases TIMP-3 and -4 in benign endometrium and endometrial cancer. Gynecol Oncol 89 3 (2003) 453-459
29. Wang F., Zhu Y., Huang Y., McAvoy S., Johnson W.B., Cheung T.H., et al. Transcriptional repression of WEE1 by Kruppel-like factor-2 is involved in DNA damage-induced apoptosis. Oncogene 24 (2005) 3875-3885
30. Vogel W.F., Abdulhussein R., and Ford C.E. Sensing extracellular matrix: an update on discoidin domain receptor function. Cell Signal 18 (2006) 1108-1116
31. Ramaswamy S., Ross K.N., Lander E.S., and Golub T.R. A molecular signature of metastasis in primary solid tumors. Nat Genet 33 (2003) 49-54
32. Yamamura H., Hirano N., Koyama H., and Takahashi K. Loss of smooth muscle calponin results in impaired blood vessel maturation in the tumor-host microenvironment. Cancer Sci 98 5 (2007) 757-763
33. Mauel S., Kruse B., Etschmann B., von der Schulenburg A.G., Schaerig M., Stovesand K., et al. Latent transforming growth factor binding protein 4 (LTBP-4) is downregulated in human mammary adenocarcinomas in vitro and in vivo. APMIS 115 6 (2007) 687-700
34. Sterner-Kock A., Thorey I.S., Koli K., Wempe F., Otte J., Bangsow T., et al. Disruption of the gene encoding the latent transforming growth factor-beta binding protein 4 (LTBP-4) causes abnormal lung development, cardiomyopathy, and colorectal cancer. Genes Dev 16 (2002) 2264-2273
35. Fu P., Thompson J.A., and Bach L.A. Promotion of cancer cell migration: an insulin-like growth factor (IGF)-independent action of IGF-binding protein-6. J Biol Chemistry 282 31 (2007) 22298-22306
36. Gorn M., Anige M., Burkholder I., Muller B., Scheffler A., Elder L., et al. Serum levels of Magic Roundabout protein in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer 49 (2005) 71-76
37. Hama K., Aoki J., Fukaya M., Kishi Y., Sakai T., Suzuki R., et al. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem 279 17 (2004) 17634-17639
38. Yang Y., Mou L.J., Liu N., and Tsao M.S. Autotaxin expression in non-small-cell lung cancer. Am J Respir Cell Mol Biol 21 (1999) 216-222
39. Zhang G., Zhao Z., Xu S., Ni L., and Wang X. Expression of autotaxin mRNA in human hepatocellular carcinoma. Chin Med J 112 (1999) 330-332
40. Chao H., Sun J., and Lu S. Bax gene expression in endometrial cancer. Zhonghua Zhong Liu Za Zhi 23 3 (2001) 214-216